Mail-Order Abortion Pills: States’ Rights Under Siege

Scales of justice with a baby figurine and a gavel in the background

Seventy-eight pro-life organizations are demanding that the Trump Justice Department stop defending Biden-era policies that allow abortion pills to be mailed across state lines, exposing a troubling disconnect between the administration’s rhetoric and its actions on protecting unborn life.

Story Snapshot

Coalition of 78 pro-life groups urges acting Attorney General Todd Blanche to reverse DOJ’s defense of mail-order abortion pill policies
Trump DOJ continues defending Biden-era FDA regulations despite Republican state lawsuits seeking to enforce abortion restrictions
Mail-order mifepristone allegedly undermines state pro-life laws enacted after Dobbs decision overturned Roe v. Wade
FDA recently approved generic abortion pills under Trump administration, signaling no immediate policy reversal

Pro-Life Coalition Challenges DOJ Stance

A broad coalition of pro-life organizations delivered a letter on April 13 to acting Attorney General Todd Blanche, pressing him to abandon the Justice Department’s defense of FDA policies permitting mail-order distribution of mifepristone. The letter, signed by 78 groups including Susan B. Anthony Pro-Life America and Students for Life Action, criticizes the DOJ for requesting courts to pause or dismiss state lawsuits challenging these regulations. Pro-life leaders argue the administration is effectively siding with the abortion industry by protecting policies that circumvent state bans enacted following the Supreme Court’s Dobbs decision.

Biden-Era Policies Continue Under Trump Administration

The controversy stems from Biden administration changes implemented between 2021 and 2023 that eliminated in-person doctor visits for obtaining mifepristone, allowing women to receive prescriptions online and have pills shipped directly to their homes. Republican state attorneys general filed lawsuits claiming these FDA regulations undermine their authority to enforce state abortion bans. The Trump DOJ, despite expectations from the pro-life base, has continued defending the FDA’s position in court, arguing that states lack standing to challenge federal drug safety determinations. This approach has persisted even after President Trump removed former Attorney General Pam Bondi and appointed Blanche to the role.

State Sovereignty Versus Federal Authority

The clash highlights fundamental tensions over federalism and states’ rights in post-Dobbs America. Republican-led states contend that FDA policies enabling interstate shipment of abortion pills effectively nullify their democratically enacted protections for unborn life. Pro-life advocates cite cases like Louisiana resident Rosalie Markezich, who they say was coerced into taking abortion pills ordered online without proper medical screening. States argue mail-order distribution creates health risks for women while making it impossible to enforce their laws. The DOJ counters that the FDA maintains authority over drug safety regardless of state abortion policies.

Growing Frustration With Government Inaction

Marjorie Dannenfelser of Susan B. Anthony Pro-Life America stated the DOJ has an opportunity to stand with states protecting women and children, but instead appears to be siding with the abortion industry. The coalition’s letter arrives as the FDA approved a new generic version of mifepristone under the Trump administration, deepening concerns among pro-life voters who expected different priorities from a Republican government. This situation reflects broader public frustration with government officials who seem more focused on maintaining bureaucratic continuity than addressing the policy concerns that motivated voters. Americans across the political spectrum increasingly question whether elected representatives serve the people or protect entrenched interests.

The letter puts Blanche in a difficult position as he manages competing pressures from the administration’s pro-life base and federal agencies defending their regulatory authority. No response from the acting Attorney General has been reported. The outcome will signal whether the Trump administration intends to align its actions with campaign promises or continue defending policies that many conservatives view as hostile to state sovereignty and the protection of unborn life.